pulmicort flexhaler- budesonide aerosol, powder
a-s medication solutions - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - pulmicort flexhaler is indicated for the maintenance treatment of asthma as prophylactic therapy in patients six years of age or older. limitations of use: the use of pulmicort flexhaler is contraindicated in the following conditions: risk summary there are no adequate well-controlled studies of pulmicort flexhaler in pregnant women. however, there are published studies on the use of budesonide, the active ingredient in pulmicort flexhaler, in pregnant women. in animal reproduction studies, budesonide, administered by the subcutaneous route, caused structural abnormalities, was embryocidal, and reduced fetal weights in rats and rabbits at less than the maximum recommended human daily inhalation dose (mrhdid), but these effects were not seen in rats that received inhaled doses approximately 2 times the mrhdid (see data ). studies of pregnant women have not shown that inhaled budesonide increases the risk of abnormalities when administered during pregnancy. experience with oral corticosteroids suggests that rod
pulmicort flexhaler- budesonide aerosol, powder
h2-pharma llc - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - pulmicort flexhaler is indicated for the maintenance treatment of asthma as prophylactic therapy in patients six years of age or older. limitations of use: •pulmicort flexhaler is not indicated for the relief of acute bronchospasm. the use of pulmicort flexhaler is contraindicated in the following conditions: risk summary there are no adequate well-controlled studies of pulmicort flexhaler in pregnant women. however, there are published studies on the use of budesonide, the active ingredient in pulmicort flexhaler, in pregnant women. in animal reproduction studies, budesonide, administered by the subcutaneous route, caused structural abnormalities, was embryocidal, and reduced fetal weights in rats and rabbits at less than the maximum recommended human daily inhalation dose (mrhdid), but these effects were not seen in rats that received inhaled doses approximately 2 times the mrhdid (see data ). studies of pregnant women have not shown that inhaled budesonide increases the risk of abnormalities when administe
fucicort cream, 20mg/g + 1mg/g
leo pharma a/s - betamethasone valerate; fusidic acid - cream - betamethasone valerate; fusidic acid - corticosteroids, dermatological preparations
fucicort cream
dksh malaysia sdn bhd - betamethasone valerate; fusidic acid -
fucicort cream
dksh singapore pte. ltd. - betamethasone valerate eqv betamethasone; fusidic acid - cream - 1 mg/g - betamethasone valerate eqv betamethasone 1 mg/g; fusidic acid 20 mg/g
pulmicort respules nebulising suspension for inhalation 0.5 mgml
astrazeneca singapore pte ltd - budesonide micronised - solution - 1 mg/2 ml - budesonide micronised 1 mg/2 ml
pulmicort respules nebulising suspension for inhalation 0.25 mgml
astrazeneca singapore pte ltd - budesonide micronised - solution - 500 mcg/2 ml - budesonide micronised 500 mcg/2 ml
pulmicort turbuhaler 200 microgram/dose
astrazeneca pty ltd - budesonide, quantity: 200 microgram/actuation - insufflation - excipient ingredients: - treatment of bronchial asthma. indications as at 3 june 1994: treatment of bronchial asthma. may also be used when replacement or reduction in oral steroid therapy is desired.
pulmicort turbuhaler 400 microgram/dose
astrazeneca pty ltd - budesonide, quantity: 400 microgram/actuation - insufflation - excipient ingredients: - treatment of bronchial asthma. indications as at 3 june 1994: treatment of bronchial asthma. may also be used when replacement or reduction in oral steroid therapy is desired.
pulmicort turbuhaler
astrazeneca limited - budesonide 100ug; ; ; - powder for inhalation - 100 mcg/dose - active: budesonide 100ug - bronchial asthma requiring maintenance treatment with glucocorticosteroids for control of the underlying airways inflammation.